Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced
Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 264 papers, 7 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
264citing papers in PubMed, 7 pooled it
34.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
264 citing papers in PubMed, 7 syntheses or guidelines pooled it, 410 citations in OpenAlex.
- Pooled it
- Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis.Journal for immunotherapy of cancer · 2025Pooled it
- Dabrafenib and trametinib vs anti-PD(L)1 for the adjuvant treatment of locally advanced BRAF-mutant melanoma: a systematic review and meta-analysis.The oncologist · 2025Pooled it
- A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research.European journal of cancer (Oxford, England : 1990) · 2025Pooled it
- Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology · 2025Guideline
- Safety and Efficacy Analysis of Targeted and Immune Combination Therapy in Advanced Melanoma-A Systematic Review and Network Meta-Analysis.International journal of molecular sciences · 2024Pooled it
- SEOM-GEM clinical guidelines for cutaneous melanoma (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib inJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial.Nature communications · 2026Trial
- Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Efficacy and safety of regorafenib in patients with advanced pretreated melanoma: results of the RegoMel phase II clinical trial.ESMO open · 2026Trial
- RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Trial
- Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.The New England journal of medicine · 2025Trial
- Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFNature medicine · 2024Trial
- Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.Nature communications · 2024Trial
- Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany.International journal of cancer · 2026Article
- Overcoming melanoma drug resistance: Mechanisms and clinical progress of oncolytic viruses combined with immune checkpoint inhibitors (Review).Oncology reports · 2026Review
- Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond.International journal of cancer · 2026Article
- Review
204 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
36 authors at 20 institutions in 1 country.
Michael B AtkinsGeorgetown Lombardi Comprehensive Cancer Center, Washington, DC.ORCID 0000-0003-3901-9924
Sandra J LeeDana-Farber Cancer Institute and Harvard Medical School, Boston, MA.ORCID 0000-0002-8626-639X
Bartosz ChmielowskiJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, Los Angeles, CA.ORCID 0000-0002-2374-3320
Ahmad A TarhiniH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.ORCID 0000-0002-3193-9702
Gary I CohenGreater Baltimore Medical Center, Baltimore, MD.ORCID 0000-0001-7510-8559
Thach-Giao TruongKaiser Permanente Northern California, Vallejo, CA.ORCID 0000-0002-6774-2557
Helen H MoonKaiser Permanente Southern California, Riverside, CA.
Diwakar DavarHillman Cancer Center and University of Pittsburgh, Pittsburgh, PA.ORCID 0000-0002-7846-8055
Mark O'RourkeGreenville Health System Cancer Institute, Greenville, SC.ORCID 0000-0003-1707-6186
Joseph J StephensonGreenville Health System Cancer Institute, Greenville, SC.
Brendan D CurtiProvidence Cancer Institute, Portland, OR.ORCID 0000-0003-3948-2708
Walter J UrbaProvidence Cancer Institute, Portland, OR.ORCID 0000-0001-8414-3348
Joanna M BrellMetroHealth Cancer Center, Case Western Reserve University, Cleveland, OH.
Pauline FunchainCleveland Clinic Taussig Cancer Center, Cleveland, OH.ORCID 0000-0002-7568-8626
Kari L KendraOhio State University Comprehensive Cancer Center, Columbus, OH.ORCID 0000-0001-5936-6689
Alexandra P IkeguchiUniversity of Oklahoma Medical Center, Oklahoma City, OK.
Anthony JaslowskiSaint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, WI.
Charles L BaneDayton Physicians LLC-Atrium, Dayton, OH.
Mark A TaylorLewis Ca & Res Pavilion at Saint Joseph's/Candler, Savannah, GA.
Madhuri BajajIllinois CancerCare-P.C., Peoria, IL.
Robert M ConryUniversity of Alabama at Birmingham, Birmingham, AL.
Robert J EllisCoxHealth South Hospital, Springfield, MO.
Theodore F LoganIndiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN.ORCID 0000-0002-9245-0820
Noel LaudiMercy Hospital, St Louis Park, MN.
Jeffrey A SosmanRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.
David G CrockettNebraska Cancer Specialists, Grand Island, NE.
Andrew L PecoraJohn Theurer Cancer Center, Hackensack, NJ.
Ian J OkazakiStraub Medical Center-Kahului Clinic, Honolulu, HI.
Sowjanya RegantiRenown Regional Medical Center, Reno, NV.
Sunandana ChandraRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.ORCID 0000-0001-7936-5069
Samantha GuildAIM at Melanoma Foundation, Richmond, CA.
Helen X ChenCancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
Howard Z StreicherCancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
Jedd D WolchokMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.ORCID 0000-0001-6718-2222
Antoni RibasJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, Los Angeles, CA.ORCID 0000-0003-3669-8458
John M KirkwoodHillman Cancer Center and University of Pittsburgh, Pittsburgh, PA.ORCID 0000-0002-3570-4476
Georgetown University · USNational Cancer Institute · USNorthwestern University · USPrisma Health · USProvidence Portland Medical Center · USUPMC Hillman Cancer Center · USAIM at Melanoma Foundation · USCleveland Clinic · USCoxHealth · USDayton Physicians Network · USGreater Baltimore Medical Center · USHackensack University Medical Center · USHarvard University · USIllinois CancerCare · USIndiana University Health · USKaiser Permanente Riverside Medical Center · USKaiser Permanente Vallejo Medical Center · USMemorial Sloan Kettering Cancer Center · USMercy Medical Center · USMetroHealth Medical Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MNRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8MMember Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MProject-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6MSWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1MWomen's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5MStatistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · 2014 to 2026
$111.2MMetro-Minnesota Community Oncology Research Consortium (MMCORC)UG1CA189863 · NCI · PARK NICOLLET INSTITUTE · PI JOLEEN M HUBBARD, Yan Ji · 2014 to 2026
$43.2MECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1MHeartland Cancer Research NCORPUG1CA189830 · NCI · DECATUR MEMORIAL HOSPITAL · PI Bryan A. Faller · 2014 to 2026
$40.9MThe Pacific Cancer Research Consortium (PCRC), an NCORP Community SiteUG1CA189953 · NCI · SWEDISH MEDICAL CENTER, FIRST HILL · PI Alison Katherine Conlin, Charles Drescher · 2014 to 2026
$27.4MTherapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-AssociateP50CA121973 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2008 to 2018
$22.9MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA121973NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180868NCI NIH HHS U10 CA180888NCI NIH HHS U24 CA196172NCI NIH HHS UG1 CA189804NCI NIH HHS UG1 CA189809NCI NIH HHS UG1 CA189822NCI NIH HHS UG1 CA189829NCI NIH HHS UG1 CA189830NCI NIH HHS UG1 CA189863NCI NIH HHS UG1 CA189953NCI NIH HHS UG1 CA189957NCI NIH HHS UG1 CA189997NCI NIH HHS UG1 CA233184NCI NIH HHS UG1 CA233193NCI NIH HHS UG1 CA233234NCI NIH HHS UG1 CA233270NCI NIH HHS UG1 CA233290NCI NIH HHS UG1 CA233320NCI NIH HHS UG1 CA233330NCI NIH HHS UG1 CA233331NCI NIH HHS UG1 CA239758NCI NIH HHS UG1 CA239769
Abstract
purposeCombination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4-blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with PATIENTS AND
methodsIn a phase III trial, patients with treatment-naive
resultsA total of 265 patients were enrolled, with 73 going onto step 2 (27 in arm C and 46 in arm D). The study was stopped early by the independent Data Safety Monitoring Committee because of a clinically significant end point being achieved. The 2-year OS for those starting on arm A was 71.8% (95% CI, 62.5 to 79.1) and arm B 51.5% (95% CI, 41.7 to 60.4; log-rank
conclusionCombination nivolumab/ipilimumab followed by BRAF and MEK inhibitor therapy, if necessary, should be the preferred treatment sequence for a large majority of patients.
Indexed as
MelanomaSkin NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsDisease ProgressionHumansImidazolesIpilimumabMitogen-Activated Protein Kinase KinasesMutationNivolumabOximesProspective StudiesProto-Oncogene Proteins B-rafPyridonesPyrimidinonesBRAF protein, humandabrafenibImidazolesIpilimumabMitogen-Activated Protein Kinase KinasesNivolumabOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.